Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Net Income towards Common Stockholders of -$92.3 million for Q1 2026, down 26.0% year-over-year from -$124.7 million in Q1 2025, and down 57.89% quarter-over-quarter from -$58.4 million in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$92.3 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$92.3 million, down 26.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$304.1 million (up 22.35% YoY), and the FY2025 annual result was -$285.0 million, up 38.82% from the prior year.
- Net Income towards Common Stockholders slipped to -$92.3 million in Q1 2026 per MDGL's latest filing, from -$58.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$42.2 million in Q2 2025 and troughed at -$152.0 million in Q2 2024.
- A 5-year average of -$89.0 million and a median of -$85.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 91.87% in 2024, then soared 72.21% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$85.9 million in 2022, then plunged by 30.6% to -$112.2 million in 2023, then surged by 47.04% to -$59.4 million in 2024, then grew by 1.63% to -$58.4 million in 2025, then plunged by 57.89% to -$92.3 million in 2026.
- Business Quant data shows MDGL's Net Income towards Common Stockholders at -$92.3 million in Q1 2026, -$58.4 million in Q4 2025, and -$111.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -92.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.28 Mn |
| Dec 31, 2025 | -58.45 Mn |
| Sep 30, 2025 | -111.12 Mn |
| Jun 30, 2025 | -42.24 Mn |
| Mar 31, 2025 | -73.24 Mn |
| Dec 31, 2024 | -59.42 Mn |
| Sep 30, 2024 | -106.96 Mn |
| Jun 30, 2024 | -151.97 Mn |
| Mar 31, 2024 | -147.54 Mn |
| Dec 31, 2023 | -112.19 Mn |
| Sep 30, 2023 | -98.74 Mn |
| Jun 30, 2023 | -85.80 Mn |
| Mar 31, 2023 | -76.90 Mn |
| Dec 31, 2022 | -85.91 Mn |
| Sep 30, 2022 | -81.20 Mn |
| Jun 30, 2022 | -70.73 Mn |
| Mar 31, 2022 | -57.52 Mn |
| Dec 31, 2021 | -64.55 Mn |
| Sep 30, 2021 | -63.10 Mn |
| Jun 30, 2021 | -61.65 Mn |